Drug Profile


Alternative Names: ONO-6950

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ono Pharmaceutical
  • Class Antiasthmatics; Butyric acids; Ethers; Fluorobenzenes; Indoles; Small molecules
  • Mechanism of Action Cysteinyl leukotriene receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 13 Sep 2015 Phase II development is ongoing in the USA
  • 13 Sep 2015 No recent reports of development identified - Phase-II for Asthma in Canada (PO)
  • 01 Jan 2015 Phase-II clinical trials in Asthma in Japan (PO) (JapicCTI-152768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top